FUTURE THERAPEUTIC TARGETS IN MANAGEMENT OF AUTOIMMUNE SKIN DISEASES

Cover Page

Abstract


Pemphigus is a severe, potentially fatal bullous skin disease, caused by desmoglein autoantibody production and immune-mediated regulation of T-cells subsets. Conventional therapy including systemic corticosteroids with or without other immunosupressants causes numerous adverse effects and becomes inefficient in refractory patients. In this work, the authors showed a modern view on the pathogenesis of pemphigus. This article describes the detailed action mechanism of rituximab, a chimeric monoclonal antibody directed against CD20 antigen of B-cells. The authors conduct the results of meta-analyses of rituximab’s efficiency in pemphigus patients. Moreover, in this article, the authors consider new promising treatment options and potential targets for biological therapy of pemphigus diseases.


A. A. Kubanova

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Author for correspondence.
Email: info@cnikvi.ru

Russian Federation

доктор медицинских наук, академик РАН, директор ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-15

A. E. Karamova

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Email: karamova@cnikvi.ru

Russian Federation

кандидат медицинских наук, ведущий научный сотрудник отдела дерматологии
ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-96

A. A. Kubanov

State Research Centre of Dermatovenereology and Cosmetology, Moscow, Russian Federation

Email: alex@cnikvi.ru

Russian Federation

доктор медицинских наук, профессор, заместитель директора ГНЦДК
Адрес: 107076, Москва, ул. Короленко, д. 3, стр. 6, тел.: +7 (499) 785-20-83

  1. Nasonov E.L. Prospects for the use of rituximab in autoimmune diseases of human. RMZh = Russian medical journal. 2007; 15 (26):1958—1963
  2. Kubanov A.A., Abramova T.V. Vestnik dermatologii i venerologii = Bulletin of dermatology and venereology. 2014; 4: 19–27.
  3. Tamgadge S.,Tamgadge A., Bhatt D.M., Bhalerao S, Pereira T. et al. Contemp. Clin. Dent. 2011; 2: 134–137.
  4. Groves R.W. Clin. Med. 2009; 9 (4): 371–375.
  5. Chmurova N., Svecova D. Bratislava Med. J. 2009; 110 (8): 500–503.
  6. Langan S.M., Smeeth L., Hubbard R., Fleming K.M., Smith C.J.P., West J. BMJ. 2008; 337: a180.
  7. Mimouni D., Bar H., Gdalevich M., Katzenelson V., David M. J. Eur. Acad. Dermatology Venereol. 2010; 24: 947–952.
  8. Yan L., Wang J.-M., Zeng K. Br. J. Dermatol. 2012; 167 (4): 768–777.
  9. Mortazavi H., Amirzargar A.A., Esmaili N., Toofan H., Ehsani A.H., Hosseini S.H. J. Dermatol. 2013; 40 (4): 244–248.
  10. Pan M., Zhu H., Xu R. J. Dermatol. 2015; 42 (1): 11–17.
  11. Meyer N., Misery L. Autoimmun. Rev. 2010; 9 (5): A379–A382
  12. Thomas M., Paul C., Berard E., Fortenfant F., Mazereeuw-Hautier J., Livideanu C. et al. Dermatology. 2010; 220 (2): 97–102.
  13. Adaskevich V.P., Kozin V.M. Kozhnye i venericheskie bolezni [Skin and Venereal Diseases]. Moscow, Med. lit., 2006. 672 p.
  14. Satyam A., Khandpur S., Sharma V.K., Sharma A. Immunol. Invest. 2009; 38 (6): 498–509.
  15. Grando S.A. Autoimmunity. 2012; 45 (1): 7–35.
  16. Pfutze M., Niedermeier A., Hertl M., Eming R. Eur. J. dermatology. 2007; 17 (1): 4–11.
  17. Hertl M., Eming R., Veldman C. J. Clin. Invest. 2006; 116 (5): 1159–1166.
  18. Wada N., Nishifuji K., Yamada T., Kudoh J., Shimizu N., Matsumoto M. et al. J. Invest. Dermatol. 2011; 131 (2): 410–417.
  19. Kim J.M., Rasmussen J.P., Rudensky A.Y. Nat. Immunol. 2007; 8 (2): 191–197.
  20. Zhu H., Chen Y., Zhou Y., Wang Y., Zheng J., Pan M. J. Clin. Immunol. 2012; 32 (1): 114–123.
  21. Giordano C.N., Sinha A.A. Autoimmunity. 2012; 45 (6): 427–439.
  22. Arakawa M., Dainichi T., Yasumoto S., Hashimoto T. J. Dermatol. Sci. 2009; 53 (3): 228–231.
  23. Xu R.-C., Li W.-P., Zhao X.-Q., Yuan H.-J., Zheng J., Pan M. Eur. J. Dermatol. 2013; 23 (6): 795–802.
  24. Thorn G.W., Forsham P.H., Frawley T.F., Hill, S.R., Roche, M., Staehelin D.W. et al. N. Engl. J. Med. 1950; 242 (22): 865–872.
  25. Mutasim D.F. Ther. Clin. Risk Manag. 2007; 3 (1): 29–40.
  26. Ruocco E., Wolf R., Ruocco V., Brunetti G., Romano F., Lo Schiavo A. Clin. Dermatol. 2013; 31 (4): 382–390.
  27. Feldman R.J., Ahmed A.R. Clin. Immunol. 2011; 7 (4): 529–541.
  28. Lunardon L., Payne A.S. G. Ital. Dermatol. Venereol. 2012; 147 (3): 269–276.
  29. Motta G., Cea M., Moran E., Carbone F., Augusti V., Patrone F. Clin Dev Immunol. 2010; 428253.
  30. Ahmed A.R., Shetty S. Autoimmun. Rev. 2015; 14 (4): 323–331.
  31. Lunardon L., Tsai K.J., Propert K.J., Fett N., Stanley J.R., Werth V.P., Tsai D.E. et al. Arch. Dermatol. 2012; 148 (9): 1031–1036.
  32. Colliou N., Picard D., Caillot F., Calbo S., Le Corre S., Lim A. et al. Sci. Transl. Med. 2013; 5 (175): 175ra30.
  33. Hertl M., Jedlickova H., Karpati S., Marinovic B., Uzun S., Yayli S.J. et al. Eur. Acad. Dermatol. Venereol. 2015; 29 (3): 405–414.
  34. Vojáčková N., Fialová J., Vaňousová D., Hercogová J. Dermatol. Ther. 2012; 25 (1): 95–97.
  35. Fiorentino D.F., Garcia M.S., Rehmus W., Kimball, A.B. Arch. Dermatol. 2011; 147 (1): 117–118.
  36. Howell S.M., Bessinger G.T., Altman C.E., Belnap C.M. J. Am. Acad. Dermatol. 2005; 53 (3): 541–543.
  37. Jacobi A., Shuler G., Hertl M. Br. J. Dermatol. 2005; 153 (2): 448–449.
  38. Lin M.-H., Hsu C.-K., Lee J.Y.-Y. Arch. Dermatol. 2005; 141 (6): 680–682.
  39. Pardo J., Mercader P., Mahiques L., Sanchez-Carazo J.L., Oliver V., Fortea J.M. 2005; 153 (1): 222–223.
  40. Ludwig R.J., Schmidt E. G. Ital. Dermatol. Venereol. 2009; 144 (4): 339–349.
  41. Church L.D., McDermott M.F. Curr. Opin. Mol. Ther. 2009; 11 (1): 81–89.
  42. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalAppli-cations/TherapeuticBiologicApplications/ucm080650.htm (accessed: 08.04.2015).
  43. Choy E.H.S., Isenberg D.A., Garrood T., Farrow S., Ioannou Y., Bird H. et al. Arthritis Rheum. 2002; 46 (12): 3143–3150.
  44. Actemra (tocilizumab) FDA Approval History - Drugs.com [Online]. Available at: http://www.drugs.com/history/actemra.html (accessed: 06.03.2015).
  45. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M. et al. Am. J. Respir. Crit. Care Med. 1999; 160 (6): 1816–1823.
  46. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P. et al. Clin. Exp. Immunol. 2002; 130 (1): 93–100.
  47. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm109106.htm (accessed: 08.04.2015).

Views

Abstract - 72

PDF (Russian) - 12

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies